BioCentury | Apr 5, 2010
Company News

Biocompatibles, Biomedical Materials, Center for Translational Molecular Medicine, Erasmus Medical Centre, Top Institute Pharma, University Medical Centre drug

The Biomedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma , all public-private partnerships, jointly awarded Biocompatibles a €6.2 million ($8.4 million) grant to develop CellBeads to treat cardiovascular diseases. Biocompatibles will...
BioCentury | Mar 15, 2010
Company News

Biocompatibles, Celsion, Cortius B.V., Glycostem Therapeutics, ISA Pharmaceuticals, IQ Corp. B.V., Percuros B.V., Biomedical Materials, Center for Translational

The Biomedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma, all public-private partnerships, jointly awarded €28 million ($38.2 million) to seven research programs, including three projects for cancer, three for drug...
BioCentury | Jan 5, 2009
Clinical News

CellBeads: Phase I/II started

Biocompatibles began an open-label, German Phase I/II trial to evaluate CellBeads in 20 stroke patients. Biocompatibles International plc (LSE:BII), Farnham, U.K. Product: CellBeads Business: Neurology Molecular target: NA Description: Beads programmed to deliver CM1, a...
Items per page:
1 - 3 of 3